ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013
PCA3 in the detection and management of early prostate cancer.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 61 citations in OpenAlex.
- Prostate cancer associated 3 (PCA3) is a potential indicator of the pathological grades of prostate cancer.Discover oncology · 2026Article
- Mitigating bias in prostate cancer diagnosis using synthetic data for improved AI driven Gleason grading.NPJ precision oncology · 2025Article
- Review
- CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.PloS one · 2024Article
- Article
- Article
- The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer.Communications biology · 2021Article
- Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer.Diagnostics (Basel, Switzerland) · 2020Article
- Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers.Frontiers in oncology · 2020Review
- For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects.International neurourology journal · 2019Article
- Emerging biomarkers in the diagnosis of prostate cancer.Pharmacogenomics and personalized medicine · 2018Review
- Article
- Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.International journal of molecular sciences · 2016Review
- Long noncoding RNAs in lung cancer: what we know in 2015.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Article
- PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.Journal of experimental & clinical cancer research : CR · 2015Article
- Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells.Cell journal · 2015Article
- Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.Cancer metastasis reviews · 2014Review
- Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).EJIFCC · 2014Article
- High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although widely used, the value of prostate-specific antigen (PSA) in the detection of prostate cancer is controversial. The percentage of free PSA increases the specificity of PSA, but results are not enough. Prostate cancer gene 3 (PCA3) has been proposed as an option that may complement these markers in the detection and management of early prostate cancer. Our aim has been to review the value of PCA3 as tumor marker. The available results suggest that PCA3 is particularly useful to select in which patients the biopsy should be repeated when the first biopsy was negative. However, some points should be specified with further studies, including the most appropriate PCA3 cutoff level and the significance of a high PCA3 score in patients with negative biopsy. False-negative results are also a conflictive point in the use of PCA3, because prostate cancer, including aggressive tumors, may be present in patients with a low PCA3 score. Probably, a proper interpretation of this test requires its management together with other tests, through multivariate models for the detection of prostate cancer. On the other hand, several studies showed the relation between PCA3 score and Gleason score, and also the utility of PCA3 to select patients for active surveillance. To summarize, the available studies show the utility of PCA3 in the detection and management of early prostate cancer, although some aspects referred to its use need to be retested after further studies to confirm the actual value and the limitations of this test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.